Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

Abstract

Background Intensive basal-bolus insulin therapy has been shown to improve glycaemic control and reduce the risk of long-term complications that are associated with type 1 diabetes mellitus. Insulin degludec is a new, ultra-longacting basal insulin. We therefore compared the efficacy and safety of insulin degludec and insulin glargine, both administered once daily with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes. Methods In an open-label, treat-to-target, non-inferiority trial, undertaken at 79 sites (hospitals and centres) in six countries, adults (aged ≥18 years) with type 1 diabetes (glycated haemoglobin [HbA(1c)] ≤10% [86 mmol/mol]), who had been treated with basal-bolus insulin for at least 1 year, were randomly assigned in a 3:1 ratio, with a computer-generated blocked allocation sequence, to insulin degludec or insulin glargine without stratification by use of a central interactive response system. The primary outcome was non-inferiority of degludec to glargine, assessed as a reduction in HbA(1c) after 52 weeks, with the intention-to-treat analysis. This trial is registered with ClinicalTrials.gov, number NCT00982228. Findings Of 629 participants, 472 were randomly assigned to insulin degludec and 157 to insulin glargine; all were analysed in their respective treatment groups. At 1 year, HbA(1c) had fallen by 0·40% points (SE 0·03) and 0·39% points (0·07), respectively, with insulin degludec and insulin glargine (estimated treatment difference -…

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(12)60204-9

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 25 references

Research works printed but not linked: 2

  1. Jonassen, 2010, Insulin degludec is a new generation ultra-long acting basal insulin with a unique mechanism of protraction based on multi-hexamer formation, Diabetes, 59, A11
  2. Heise, 2011, The pharmacodynamic variability of insulin degludec is consistently lower than insulin glargine over 24 hours at steady state, Diabetes, 60, A263

Cited by

See all 402

Metadata

Authors
Heller, S., Buse, J., Fisher, M., Garg, S., Marre, M., Merker, L., Renard, E., Russell-Jones, D., Philotheou, A., Francisco, A. M. O., Pei, H., & Bode, B.
Affiliations
  • University of Sheffield (GB)
  • University of North Carolina at Chapel Hill (US)
  • Glasgow Royal Infirmary (GB)
  • Assistance Publique – Hôpitaux de Paris (FR)
  • Kreiskrankenhaus Dormagen (DE)
  • Royal Surrey County Hospital (GB)
  • University of Cape Town (ZA)
  • Novo Nordisk (Denmark) (DK)
  • Atlanta Diabetes Associates (US)
Corresponding author
Heller, Simon
Venue
The Lancet
Publisher
Elsevier BV
Published
2012-04
Volume
379
Issue
9825
Pages
1489-1497
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2106459655
Cited by
402
References
25
Citations by year
2026: 1 · 2025: 7 · 2024: 9 · 2023: 19 · 2022: 16 · 2021: 20 · 2020: 12 · 2019: 24 · 2018: 31 · 2017: 28 · 2016: 35 · 2015: 51 · 2014: 55 · 2013: 69 · 2012: 25
FWCI
51.33
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
  • Open Research (University of Surrey) (submittedVersion)
  • Surrey Research Insight Open Access (The University of Surrey) (submittedVersion)
Funders
Novo Nordisk
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
Keywords
insulin degludec, insulin glargine, type 1 diabetes, multiple daily insulin injections, insulin aspart, HbA1c, glycemic control, non-inferiority, hypoglycemia, HbA1c targets, insulin dose
MeSH terms
Insulin Glargine, Adult, Diabetes Mellitus, Type 1, Drug Administration Schedule, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Insulin, Long-Acting, Insulin Aspart

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. https://app.cochat.ai/papers/10.1016/s0140-6736(12)60204-9
The paper
Heller, S., Buse, J., Fisher, M., Garg, S., Marre, M., Merker, L., Renard, E., Russell-Jones, D., Philotheou, A., Francisco, A. M. O., Pei, H., & Bode, B. (2012). Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. The Lancet. https://doi.org/10.1016/s0140-6736(12)60204-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.